The FTC’s Covetrus–MWI Challenge: Merger-Enforcement Lessons for Concentrated Distribution Markets

Veterinary distribution rarely makes front pages. On Friday, November 13, 2026, it did. Reuters, Seeking Alpha, MLex, Semafor, dvm360 and a run of local outlets in the joining states reported the FTC’s latest merger challenge within hours. It is a familiar type of case, with two close rivals in a concentrated market. It is also one of the more instructive enforcement actions of the year.

Our legal briefing note covered the filing. This analysis draws on wider coverage and Google Trends data to set out what the case means for lawyers, deal teams and buyers in concentrated supply markets. This is not legal advice. Consult counsel on specific antitrust or contractual questions.

The deal and the challenge

Covetrus, based in Portland, Maine, and owned by private-equity firms Clayton, Dubilier & Rice and TPG, agreed in February 2026 to acquire MWI from pharmaceutical distributor Cencora. According to dvm360, Cencora would receive $1.25 billion in cash, $800 million in preferred equity and $1.45 billion in common equity, keeping a 34.3% non-controlling stake in the combined business. The companies presented it as a single platform covering product distribution, practice technology and services. Covetrus CEO Ben Wolin said at the time the combination was “about making animal health care more affordable and accessible.”

The FTC disagrees. Its complaint, filed in the US District Court for the Southern District of New York, says Covetrus and MWI are each other’s closest competitors in two markets:

• Distribution to veterinary clinics, covering pharmaceuticals, vaccines, surgical supplies and “white goods” such as gloves, gauze and syringes, across thousands of products.
• Distribution to large corporate accounts, meaning consolidated practice groups that operate hundreds of clinics.

Attorneys general from Arizona, Arkansas, California, Colorado, Maine, Michigan, Minnesota, Nebraska, New York, North Carolina, Ohio, Oregon and Texas joined. The Commission voted 2-0 to authorize staff to seek a permanent injunction. “Covetrus wants to eliminate its closest competitor rather than compete for veterinary clinic customers,” said Daniel Guarnera, director of the FTC’s Bureau of Competition.

The FTC’s theory: head-to-head rivalry and a price-comparison platform

The complaint is detailed on competitive dynamics. According to dvm360’s summary, the FTC alleges that Covetrus matched MWI on price through cuts and rebates under its VetSuite programme. It also says Vetcove, an online platform that lets veterinarians compare distributor prices and use one quote to negotiate with the other, intensified the rivalry into what the complaint calls an “all-out price war.”

That point matters beyond this case. Enforcers increasingly point to digital price-transparency tools as evidence of how competition actually works, and as something a merger would neutralize. If two rivals are the only meaningful options on a comparison platform, combining them removes the main benefit buyers get from it.

The FTC also argues that specialty distributors, manufacturers selling direct, retailers and other “fringe” suppliers do not meaningfully constrain the two leaders. It points to national distribution networks and rebate programmes that smaller rivals cannot match. The agency says the result would be highly concentrated markets, presumptively unlawful under case law and the 2023 FTC–DOJ Merger Guidelines. The public release did not give market-share figures. Earlier reporting in the Daily Caller suggested the combined company could hold up to 75% of the relevant market, but that figure is not corroborated by the agency, so treat it as unverified.

Covetrus’s defence: the market is wider than the FTC says

Covetrus answered the same day. It said the lawsuit “does not reflect an accurate understanding of how veterinarians actually buy the products they need.” Its main arguments are:

• Fifteen years of industry change have given practices more purchasing options than ever.
• Clinics, including large groups, routinely buy the same products from more than one supplier, order several times a week and negotiate directly with manufacturers.
• All suppliers rely on the same national carriers, which lowers distribution barriers.
• Retailers now sell flea and tick treatments, pharmaceuticals and prescription pet foods directly to pet owners, bypassing both distributors and clinics.

That sets up a classic market-definition fight. The FTC wants a narrow market (full-line distribution to clinics). Covetrus wants a broad one (all channels through which animal-health products reach the end customer). How the court defines the market will largely decide the case.

What the search data says

Google Trends shows that interest in “Covetrus” had already been elevated for weeks. It peaked on October 26, which matches earlier reporting on the FTC’s review and the parties’ remedy proposals. Interest then climbed again in the days around the filing, reaching 86 on the index on November 13. Searches for the generic phrase “FTC merger” doubled in the week of the filing. The US accounted for the most searches, followed by the Netherlands (72), Switzerland, Belgium and the UK. That pattern points to interest from European animal-health manufacturers and investors, not just US veterinarians.

The data suggests readers fall into two groups: practitioners asking what the case means for their supplier, and deal professionals tracking FTC enforcement. This guide covers both.

Five lessons for deal teams and general counsel

1. Remedy offers do not guarantee clearance

MLex reported in October that Covetrus and MWI had proposed remedies to the FTC and a dozen states. The agency sued anyway. When two merging parties are each other’s closest rival in the core market, divestitures that leave a weaker third player often fail to persuade today’s FTC. Deal teams should model a litigated outcome early and price that risk into break fees and timelines.

2. Private-equity buyers face full scrutiny

The complaint names Covetrus’s owners, CD&R and TPG, as defendants. That fits a sustained bipartisan focus on private-equity roll-ups in healthcare, including veterinary care. Sponsors pursuing platform deals in fragmented healthcare markets should expect the agencies to look at the sponsor’s whole portfolio and acquisition history, not only the target.

3. State attorneys general are equal partners

A bipartisan group of 13 states, from California and New York to Texas and Nebraska, joined the complaint. State AGs bring their own investigative powers, their own settlement leverage and, increasingly, their own pre-merger notification laws. Plan for the states from day one, not as an afterthought.

4. Your customers’ tools are evidence

The Vetcove allegations show that agencies will use procurement platforms, rebate programmes and customer switching data to prove head-to-head competition. Internal documents describing a rival as the “main threat,” or price-match programmes aimed at one competitor, can be decisive. Antitrust counsel should review deal rationale and integration documents with that in mind.

5. Market definition is the battleground

Covetrus’s defence depends on omnichannel buying: online retail, direct-from-manufacturer sales and multi-sourcing. If your industry is going through a similar channel shift, build the evidence well before signing a deal: customer surveys, switching data and win-loss records showing that new channels actually discipline prices.

What procurement and practice leaders should do now

For veterinary groups and anyone buying from Covetrus or MWI, the litigation creates near-term uncertainty, not immediate change. Practical steps:

• Map your contracts: Note renewal dates, volume commitments and rebate tiers with both distributors that fall between now and mid-2027.
• Keep dual sourcing: The FTC’s case rests on the value of competition between these two suppliers. While the case runs, that competition continues. Use it.
• Document pricing: Keep records of quotes and price-match outcomes. If the deal is later cleared or settled, they give you a baseline for measuring post-merger price changes.
• Watch software links: Covetrus also runs a widely used practice-management platform (Bloomberg has estimated about 25% share). Practices on that software should review data-portability and integration terms whatever the litigation outcome.

What to watch next

• December 4, 2026: The temporary restraining order expires unless extended. Watch for a preliminary-injunction schedule.
• Preliminary-injunction hearing: In most FTC merger challenges this is the decisive event. Parties often abandon a deal after losing at this stage.
• Cencora’s options: Analysts have noted Cencora could look for another buyer or a different structure for MWI if the deal fails.
• Settlement signals: Any revised remedy package, including divestitures of distribution centres, customer contracts or software assets.
• Other healthcare distribution deals: The reasoning here will be cited in future reviews of medical, dental and pharmacy distribution mergers.

Frequently asked questions

What is the Covetrus–MWI deal worth?
About $3.5 billion. Cencora would receive cash, preferred equity and common equity and keep a 34.3% stake in the combined company.

Where is the case filed and who joined?
In the US District Court for the Southern District of New York. Thirteen states joined: Arizona, Arkansas, California, Colorado, Maine, Michigan, Minnesota, Nebraska, New York, North Carolina, Ohio, Oregon and Texas.

Can the merger close now?
No. The parties agreed to a temporary restraining order that bars closing until at least December 4, 2026. A court must then rule on the FTC’s request for a preliminary injunction.

Will veterinary prices change immediately?
No. While the litigation continues, Covetrus and MWI remain separate competitors. Long-term effects depend on how the case is resolved.

Sources and further reading

• dvm360: FTC sues to block Covetrus’ merger with MWI Animal Health (November 13, 2026)
• Federal Trade Commission press release and complaint, FTC et al. v. Covetrus Inc. et al., S.D.N.Y., November 13, 2026
• Covetrus statement on the FTC decision to challenge the proposed merger, PR Newswire, November 13, 2026
• Reuters, Semafor, MLex, Seeking Alpha, Today’s Veterinary Business and Bovine Veterinarian coverage, November 13, 2026 (via Google News RSS)
• MLex: Covetrus, MWI propose remedies in US review of $3.5 billion deal
• Google Trends: “Covetrus”, past 30 days